Wound Closure and Advanced Wound Care Market: as CMS’s December 24, 2025 withdrawal of its finalized skin substitute coverage restrictions preserved broader Medicare access to cellular and tissue-based products just one week before a narrower, 18-product coverage list would have taken effect, manufacturers such as Kerecis and Celularity that had publicly highlighted their products’ continued eligibility under legacy coverage rules found their competitive position affirmed by regulatory reversal rather than product performance alone, so this market is now operating on genuinely two speeds, a standard closure segment commoditising around price and an advanced bioactive segment where regulatory standing has become as commercially decisive as clinical differentiation.

The global wound closure and advanced wound care market size was USD 26.72 Billion in 2025 and is expected to register a revenue CAGR of 6.2% during the forecast period. Market revenue growth is driven by factors such as rising surgical procedure volumes sustaining structural demand for suture, staple, and adhesive wound closure products, continued innovation in advanced bioactive dressing and negative pressure wound therapy technology expanding chronic wound management capability, and the December 2025 CMS reversal on skin substitute coverage restrictions preserving broader market access for cellular and tissue-based product manufacturers. The first driving factor is rising global surgical procedure volumes, sustaining structural demand for the sutures, staples, and tissue adhesives that virtually every surgical procedure requires for wound closure. Every surgical incision requires a wound closure method, whether sutures, staples, or tissue adhesive, and rising global surgical procedure volume across both inpatient and ambulatory settings directly sustains structural demand for this foundational product category. The second driving factor is continued innovation in advanced bioactive dressing and negative pressure wound therapy technology, expanding chronic wound management capability beyond what standard wound closure products alone can address. Chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers, often fail to heal through standard wound closure approaches alone and increasingly require advanced bioactive dressings or negative pressure wound therapy to achieve wound closure. The third driving factor is the December 2025 CMS reversal on skin substitute coverage restrictions, preserving broader Medicare market access for cellular and tissue-based product manufacturers that had faced a substantially narrower approved product list under the withdrawn coverage determinations. These are some of the key factors driving revenue growth of the market.

A second layer of demand comes from the way a reversed regulatory restriction can affirm a manufacturer’s existing market position without requiring any new product approval or clinical differentiation, letting continued Medicare coverage eligibility under legacy rules translate directly into sustained commercial access for manufacturers whose products would otherwise have faced exclusion under the withdrawn, narrower coverage list. Once CMS finalizes a coverage determination limiting Medicare-reimbursed cellular and tissue-based product access to a defined list of evidence-meeting products, manufacturers whose products fall outside that list face a direct commercial access barrier regardless of their products’ actual clinical performance, so when CMS subsequently withdraws that same restrictive coverage determination, manufacturers previously facing exclusion regain broader market access purely through the regulatory reversal itself, independent of any new clinical evidence or product improvement. As a result, demand and competitive positioning in the advanced bioactive dressing segment are concentrating around manufacturers who both maintained broad legacy coverage eligibility through 2025’s regulatory volatility and continue investing in clinical evidence generation for the eventual, still-uncertain future coverage framework, and the forecast tilts toward this dual-track competitive strategy capturing disproportionate share rather than manufacturers relying on regulatory outcome alone. For instance, following CMS’s December 24, 2025 withdrawal of finalized Local Coverage Determinations that would have limited Medicare-reimbursed skin substitute coverage to 18 specific evidence-meeting products, manufacturers including Kerecis, whose fish-skin-based products, and Celularity, whose Biovance products, had publicly highlighted their continued broader coverage eligibility under legacy policy, found their competitive market access preserved by the regulatory reversal rather than requiring a new product-specific coverage determination. These are some of the key factors driving revenue growth of the market.

The clearest driver of demand is the direct, mechanical relationship between global surgical procedure volume and wound closure product consumption, since every surgical incision requires a closure method regardless of specialty or setting. A surgical procedure cannot be completed without closing the incision through sutures, staples, or tissue adhesive, and this clinical necessity applies to virtually every surgical procedure performed globally, so surgical procedure volume growth and wound closure product demand growth are directly and mechanically linked. Global surgical procedure volume continues to grow steadily across both inpatient hospital and ambulatory surgical centre settings, sustaining structural demand for the wound closure products every procedure requires. The effect on the market is that wound closure product unit demand growth tracks underlying global surgical procedure volume growth relatively closely, even where value growth lags in the increasingly commoditised standard closure segment. These are some of the key factors driving revenue growth of the market.

The second driver is CMS’s abrupt reversal of finalized skin substitute coverage restrictions, which directly preserved market access for manufacturers whose products would otherwise have faced Medicare coverage exclusion under a substantially narrower approved product list. A finalized coverage determination limiting Medicare-reimbursed skin substitute access to a defined list of evidence-meeting products creates a direct commercial exclusion risk for manufacturers whose products fall outside that list regardless of actual clinical performance, and when CMS subsequently withdraws that restrictive determination, previously at-risk manufacturers regain broader market access purely through this regulatory reversal, so the coverage determination’s finalization and its subsequent withdrawal are each independently consequential commercial events for affected manufacturers. CMS finalized Local Coverage Determinations in December 2025 that would have limited Medicare reimbursement to 18 specific skin substitute products meeting rigorous evidence thresholds while excluding 158 others, before announcing the immediate withdrawal of these same LCDs on December 24, 2025, just one week before their scheduled January 1, 2026 effective date. The recent record shows the pace. Manufacturers including Kerecis and Celularity publicly highlighted that their products maintained broader coverage eligibility under the legacy policy framework the withdrawal preserved, avoiding the exclusions that would have affected competitors under the narrower withdrawn list. The effect on the market is that advanced bioactive dressing manufacturer competitive positioning has been directly shaped by this regulatory reversal, independent of any new clinical evidence or product-specific approval. These are some of the key factors driving revenue growth of the market.

“CMS finalized Local Coverage Determinations in December 2025 limiting Medicare reimbursement to 18 specific skin substitute products while excluding 158 others, before withdrawing these same LCDs on December 24, 2025, just one week before their scheduled effective date, preserving the broader market access that manufacturers including Kerecis and Celularity had publicly relied on under the legacy coverage framework.”

The third driver is continued technology innovation across advanced bioactive dressing and negative pressure wound therapy product categories, extending effective treatment capability to chronic wounds that standard closure approaches alone often cannot heal. Chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers, frequently fail to progress toward closure through standard wound care approaches alone due to underlying vascular disease, diabetes, or pressure-related tissue damage, and advanced bioactive dressings and negative pressure wound therapy directly address these underlying healing barriers in ways standard closure technology cannot. Chronic wounds increasingly require advanced bioactive dressings or negative pressure wound therapy to achieve wound closure where standard approaches have proven insufficient, reflecting the genuine clinical necessity driving this technology category’s continued adoption. The effect on the market is that advanced bioactive dressing and NPWT technology adoption continues expanding specifically among the chronic wound patient population that standard wound closure products alone cannot adequately serve. These are some of the key factors driving revenue growth of the market.

However, the wound closure and advanced wound care market faces severe adoption constraints from commoditisation of standard closure products constraining pricing power across the largest-volume category, reimbursement complexity for bioengineered therapies creating genuine near-term uncertainty for the advanced segment, and group purchasing organisation contract consolidation reinforcing price as the primary competitive dimension in standard closure specifically. Because standard sutures, staples, and tissue adhesives have substantially standardised across compliant suppliers meeting recognised performance and regulatory requirements, hospital procurement committees increasingly treat this segment as a price-and-reliability decision, directly limiting the pricing power any individual manufacturer, including established suppliers with strong brand reputations, can sustain across the largest-volume portion of total wound closure category purchasing. Reimbursement complexity for bioengineered therapies is a second constraint, since the skin substitute and cellular/tissue-based product segment underwent repeated coverage determination delays, a full payment methodology restructuring, detailed product-eligibility restrictions, and a last-minute withdrawal all within a single calendar year, and even following the December 2025 reversal, manufacturers and providers continue operating without a fully settled, durable long-term coverage framework for this specific advanced product category. Group purchasing organisation contract consolidation is the third constraint, since large-scale hospital group purchasing organisation contracts concentrate substantial standard wound closure procurement volume within a small number of contract awards, further reinforcing price as the primary competitive dimension in this specific segment while leaving less room for advanced bioactive product differentiation to influence broader contract-level purchasing decisions. These factors substantially limit wound closure and advanced wound care market growth over the forecast period.

Based on product type, the global wound closure and advanced wound care market is segmented into sutures/staples/tissue adhesives, advanced bioactive dressings, and negative pressure wound therapy (NPWT). Sutures, staples and tissue adhesives hold the largest revenue share, because they represent the foundational, highest-volume wound closure category required across virtually every surgical procedure regardless of specialty. Advanced bioactive dressings are expected to register a significantly large revenue share in the global wound closure and advanced wound care market over the forecast period, reflecting their essential clinical role in chronic wound management alongside the CMS coverage stability the December 2025 reversal preserved for leading manufacturers including Kerecis and Celularity.

Surgical wound closure application is expected to account for the largest revenue share in the global wound closure and advanced wound care market during the forecast period

Based on application, the global wound closure and advanced wound care market is segmented into surgical wound closure and chronic wound management. Surgical wound closure holds the largest revenue share, reflecting the direct, mechanical link between global surgical procedure volume and wound closure product demand across every surgical specialty. Chronic wound management is expected to register the fastest revenue growth rate in the global wound closure and advanced wound care market over the forecast period, driven directly by advanced bioactive dressing and NPWT technology innovation, which is why this application represents the leading edge of technology investment within the broader market.

Based on regional analysis, the wound closure and advanced wound care market in North America accounted for largest revenue share in 2025. The United States leads because it hosts the largest concentration of surgical procedure volume and advanced wound care spending globally, and because Johnson & Johnson MedTech, Medtronic, and Solventum all concentrate significant commercial activity in the country. The CMS skin substitute reimbursement reform and its December 2025 reversal applies specifically within the United States Medicare framework, directly shaping domestic advanced bioactive dressing manufacturer competitive positioning. The concentration of the largest surgical procedure volume base and direct CMS regulatory jurisdiction in the United States also means new wound closure and advanced wound care reimbursement policy developments are typically most consequential in the United States first.

The market in Europe is expected to register a steady revenue growth rate over the forecast period. Germany, the United Kingdom, and France represent the three largest national wound closure and advanced wound care markets within Europe. The region’s established national health system surgical and wound care infrastructure and CE-marking regulatory pathway under the Medical Device Regulation sustain steady demand. The result is steady rather than rapid growth, shaped more by the region’s already-mature surgical infrastructure than by the specific reimbursement volatility currently affecting the United States skin substitute segment.

The market in Asia Pacific is expected to register a rapid revenue growth rate over the forecast period. China, Japan, and India represent the three largest national wound closure and advanced wound care markets within the region. Expanding hospital surgical infrastructure investment and rising chronic wound prevalence in China and India are driving new demand from a comparatively lower installed base, leaving more room for growth than in the already-mature North America and Europe markets.

The market in Latin America is expected to register a moderate revenue growth rate over the forecast period. Brazil and Mexico represent the two largest national wound closure and advanced wound care markets within the region. Hospital surgical and wound care clinic networks in both countries continue gradually expanding advanced technology adoption, and the indirect effects of Iran-US sanctions and the associated Strait of Hormuz shipping disruption have kept freight and import costs elevated for the specialised wound closure and advanced wound care products that Latin American healthcare systems depend on through 2026, slowing adoption beyond the region’s main urban centres.

The market in Middle East and Africa is expected to register a moderate revenue growth rate over the forecast period. Saudi Arabia and the UAE represent the primary commercial wound closure and advanced wound care markets within the GCC. The UAE is the most established wound closure and advanced wound care market on the continent given its concentrated private hospital surgical infrastructure, while the wider Gulf states and broader African markets are still building the healthcare infrastructure that advanced wound care product adoption depends on.